Periodic Reporting for period 1 - CB-103 (First effective targeted therapy for T-cell acute lymphoblastic leukemia (T-ALL) and other NOTCH pathway driven cancers)
Reporting period: 2019-06-01 to 2019-09-30
Cellestia Biotech AG (Cellestia) was founded in 2014 as a spin-off from Ecole Polytechnique Fédérale de Lausanne, Switzerland (EPFL). The company is actively engaged in clinical development of first-in-class targeted therapeutics with untapped mode of action, to address unmet medical need in patients with oncology and immunological disorders. Their mission is to develop the CB-103, a novel, first-in-class, oral pan-NOTCH inhibitor with a unique mode of action for treatment of NOTCH dependent leukaemia, lymphomas and solid tumours. The team is currently working towards establishing clinical safety and efficacy of the drug through phase Ib and phase IIa clinical trials. The key development and commercialisation objectives are to manufacture CB-103 for clinical trials, to successfully perform phase Ia and phase IIb clinical trials and then out-license further stages of pivotal trials and EMA/FDA approval to partner pharma companies. Cellestia undertook the feasibility study to determine whether the precision oncology solution and business model were scalable, cost-effective and profitable, and to identify any strengths and weaknesses moving forward.
Cellestia’s highly disruptive CB-103 pan-NOTCH targeted therapy will offer several medical benefits to Europe and the world. It has been estimated that about 250,000 oncology patients are affected by NOTCH-dependent cancers worldwide. However, the currently available therapies only treat efficiently the few T-ALL cases that are not relapse or refractory, and most of the patients do not respond to conventional treatments, reducing their life expectancy down to 10%, without any available therapies. These patients also have to deal with high costs associated with current treatments. Cancer diagnosis and treatment costs approximately €35,000 per patient and, by 2020, this is expected to rise to €47,000. Blood cancers, in particular, are very expensive to both patients and the healthcare system. CB-103 is expected to have a major impact on the quality of life and survival prospects for all T-ALL patients.